A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab
This study will characterize the movement of drugs within the body, evaluate safety and determine to which extent the body can process relatlimab in combination with nivolumab in subjects with certain advanced tumors
Cancer
DRUG: relatlimab|DRUG: nivolumab|DRUG: rHuPH20
maximum observed serum concentration (Cmax), approximately 60 days|time of maximum observed serum concentration (Tmax), approximately 60 days|area under the time-concentration curve over the dosing interval AUC (TAU), approximately 60 days|Observed concentration at the end of the dosing interval (Ctau), approximately 60 days|Incidence of Serious Adverse Events (SAEs), approximately 2 years|Incidence of Adverse Events (AEs), approximately 2 years|Incidence of Adverse Events leading to discontinuation, approximately 2 years|Number of deaths, approximately 2 years|Number of laboratory abnormalities, approximately 2 years
Incidence of Adverese Events (AEs) in the broad SMQ of Anaphylactic Reaction, approximately 2 years|Number of events within the hypersensitivity/infusion reaction select AE category, approximately 2 years|Incidence of anti-relatlimab antibodies and neutralizing antibodies (if applicable), approximately 2 years|Incidence of anti-nivolumab antibodies and neutralizing antibodies (if applicable), approximately 2 years
This study will characterize the movement of drugs within the body, evaluate safety and determine to which extent the body can process relatlimab in combination with nivolumab in subjects with certain advanced tumors